Anumana Named to Fierce Medtech’s 2022 Fierce 15
CAMBRIDGE, Mass. , March 20 /Businesswire/ - Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has been named one of Fierce Medtech’s 2022 Fierce 15. This prestigious honor indicates that the two-year-old company is well-positioned to transform cardiac care by leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart.
“We are honored to be recognized as one of the Medtech Fierce 15 companies for 2022,” said David McMullin, Chief Business Officer of Anumana. “Anumana’s goal is to decode electrical signals from the heart as never before, empowering healthcare providers to improve patient care throughout the cardiac clinical pathway. We are excited to continue developing innovative solutions to the most pressing challenges facing cardiovascular disease diagnosis, treatment, and management.”
Powered by nference’s nSights data platform, Anumana leverages ECG waveforms from the heart with deep, longitudinal electronic medical records (EMR) data at the patient level, developing state-of-the-art algorithms aimed to help physicians diagnose and treat cardiac disease earlier and more efficiently. Nference, which partners with leading healthcare systems such as Mayo Clinic and Duke Health, makes real-world data available includes multiple data modalities (clinical, molecular, and imaging).
Anumana’s algorithms for early detection of low ejection fraction, pulmonary hypertension, and hyperkalemia, have received Breakthrough Device Designation from the U.S. FDA. Its robust pipeline of FDA-ready algorithms has been validated with significant prospective clinical evidence in over 75 peer-reviewed publications - including two first-of-their-kind studies published in Nature Medicine and The Lancet. Anumana develops these algorithms in collaboration with the Mayo Clinic Platform and has received sponsorship from strategic pharmaceutical leaders such as Janssen, Novartis, and Pfizer to further develop and commercialize ECG-AI algorithms.
Anumana’s AI platform utilizes widely accessible screening tools and is built to seamlessly integrate into existing clinical workflows, providing clinicians with real-time insights, accelerating the time to guideline-directed medical therapy, reducing costs, and improving patient outcomes. Anumana seeks regulatory clearances for the platform as software as a medical device (SaMD) and has early milestones for reimbursement in place with two Category III CPT® codes that became effective January 1st, 2023.
Fierce Medtech’s Fierce 15, launched in 2012, is an annual special report that spotlights the most exciting startups in medtech. This year’s report features the 15 medtech startups that made the biggest splashes in 2022 and aimed to pick the players they think are “the most capable of delivering on their promises to advance the art and science of healthcare.”
About Anumana
Anumana, an AI-driven health technology company and portfolio company of nference, is leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and other leading institutions to detect hidden diseases using AI-ECG algorithms and to enhance and improve interventional procedures through real-time AI insights. Multiple Anumana algorithms have received FDA Breakthrough Device Designation and are currently undergoing rigorous clinical validation. Anumana software devices are designed for real-world physician use, integrating into existing workflows at the point of care to reduce costs and enhance quality of life. Anumana algorithms are investigational medical devices and have not yet received regulatory approval or clearance. For more information, visit anumana.ai and follow Anumana on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230320005466/en/
